Abstract

<h3>Purpose/Objective(s)</h3> Ventricular tachycardia (VT) is characterized by electrical re-entry within patches of heterogeneous myocardial fibrosis leading to sustained consecutive ventricular beats at a rate > 100 per minute. Catheter ablation is the standard of care adjunctive therapy for patients who are refractory to medical therapy to destroy the pathways responsible for these arrhythmias. Recently, a novel treatment approach using ablative radiation with stereotactic body radiation therapy (SBRT) to the arrhythmogenic scar regions defined by noninvasive cardiac mapping has been described for patients refractory to standard-of-care therapies. We describe our experience with 6 patients treated with this technique in our institution. <h3>Materials/Methods</h3> All 6 patients had refractory VT with previously failed ablations and at least one anti-arrhythmic drug. Patients were simulated with 4D computed tomography (4D-CT) and targets were defined using the combined information from cardiac mapping, diagnostic and simulation imaging with cardiologists, medical physicists, and radiation oncologists for each patient. An internal target volume was created based on the cardiac and respiratory motion. An isotropic margin of 3 mm was added to create the planning target volume (PTV). The PTVs were prescribed 25 Gy in 1 fraction normalized so 95% of the PTV was covered by the 25 Gy isodose. Radiation was delivered using volumetric modulated arc therapy. Patients were evaluated immediately following treatment for acute side effects, and then at 6 weeks, 3 months, 6 months, and then yearly. Implantable cardioverter defibrillator (ICD) interrogation was performed regularly by the treating cardiologist to assess the number of VT and ICD events. <h3>Results</h3> All 6 patients tolerated treatment with no immediate acute side effects. One patient experienced mild esophagitis in the first 3 weeks following treatment which resolved. 4 of 6 patients had immediate significant reduction in the number of VT and ICD events in the first 6 months after treatment (>90%), however, one patient did not respond and required an extracorporeal membrane oxygenation assisted ablation 3 months later. The first two patients treated have had longer follow-up and one remains VT-free and has stopped anti-arrhythmic drugs, however, another has relapsed 2 years following radiotherapy in an area of the arrhythmogenic substrate that was intentionally not irradiated due to organ at risk safety concerns. <h3>Conclusion</h3> Despite increasing reports in the literature, there are no established criteria to predict success for this treatment, making it difficult to identify optimal patients. Current limited evidence suggests that this technique may be a relatively safe approach that provides an acute reduction in VT burden for those that have run out of conventional treatment options.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.